Risultati della ricerca per “Nuovo farmaco per la malattia di Crohn e colite ulcerosa” – Pagina 5

In Lombardia uno studio pilota promosso da Telethon coinvolgerà 100mila neonati. Obiettivo: validare il test per la diagnosi di leucodistrofia metacromatica

Risultati per: Nuovo farmaco per la malattia di Crohn e colite ulcerosa

High-Dose Upadacitinib Therapy for Refractory Metastatic Crohn Disease

Al via screening neonatale contro malattia neurodegenerativa

Disforia di genere, si cambia: sotto la lente il farmaco che blocca la pubertà

Su1876 TESTING THE DEVELOPMENT OF TWO EDUCATIONAL SOCIAL MEDIA VIDEOS FOR PATIENTS WITH CROHN'S PERIANAL FISTULA: A HUMANCENTERED DESIGN STUDY

Su1875 UNDERSTANDING HOW PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE DESCRIBE THE SPECTRUM OF BOWEL URGENCY DEFINITIONS: RESULTS FROM QUALITATIVE RESEARCH

Su1874 THE BURDEN OF MENTAL HEALTH DISEASE IN PEOPLE WITH INFLAMMATORY BOWEL DISEASE – CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM

Su1873 ACTIVE PERIANAL CROHN'S DISEASE NEGATIVELY IMPACTS PATIENTS’ QUALITY OF LIFE, AND WELLBEING, INFLUENCED BY SOCIAL DETERMINANTS OF HEALTH

Su1866 MIRIKIZUMAB IMPROVES FATIGUE, BOWEL URGENCY, AND QUALITY OF LIFE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM A PHASE 3 CLINICAL TRIAL

Su1863 IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE ITEMS FATIGUE, DEPRESSION, ANXIETY, AND BOWEL URGENCY IN PATIENTS WITH CROHN'S DISEASE TREATED WITH UPADACITINIB IN PHASE 3 TRIALS

Su1841 VARIATION IN OUTCOMES IN INFLAMMATORY BOWEL DISEASE AT TEN AUSTRALASIAN CENTRES – CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM

Su1839 IDENTIFICATION OF CLINICAL RISK FACTORS FOR POSTOPERATIVE ENDOSCOPIC RECURRENCE IN CROHN'S DISEASE: A PROSPECTIVE, MULTICENTER COHORT STUDY

Su1838 REAL LIFE MANAGEMENT OF PATIENTS WITH ACTIVE PERIANAL FISTULIZING CROHN'S DISEASE (ALERT-CD STUDY)

Su1829 THE INTRA-PATIENT VARIABILITY OF ADALIMUMAB CLEARANCE DURING AN INTENSIVE SAMPLING STUDY OF CROHN'S DISEASE PATIENTS RECEIVING MAINTENANCE THERAPY

Vuoi restare informato delle novità di Meditutor?

Iscriviti alla newsletter.

Confermo di aver preso visione dell'informativa in questa pagina